Leading pipelines
- Target Type
- Tau (acetylated lysine 280, acK280)
- Modality
- monoclonal antibody (humanized)
- Indication
- Alzheimer's disease or Tauopathy (rare disease)
- Development stage
- Clinical, phase 1 (USA FDA)
- Target Type
- MHC-I - free (unbound), β2-microglobulin (β2m)
- Modality
- monoclonal antibody
- Indication
- Alzheimer's Disease, Aging, Fibrosis (Kidney, Liver, Lung), Cancer, Inflammation
- Development stage
- Preclinical efficacy
- Target Type
- ApoE4
- Modality
- monoclonal antibody
- Indication
- Alzheimer's Disease, Metabolic disease
- Development stage
- Preclinical efficacy
- Target Type
- Androgen Receptor, Tau aggregates
- Modality
- small molecule
- Indication
- Prostate cancer, Alzheimer’s Disease
- Development stage
- Hit-to-Lead
- Target Type
- phosphorylated Tau (T217)
- Modality
- monoclonal antibody
- Indication
- Alzheimer's Disease, Dementia, Tauopathy
- Development stage
- Diagnostic product development in progress
